Tell the clinician about tadalafil before considering Priligy, whether tadalafil is taken regularly, occasionally or in a combined sexual-function product. A medicine remains relevant to safety screening when it was prescribed for another concern or taken on a different schedule.
The cited Irish Priligy information advises against use in patients taking PDE5 inhibitors, including tadalafil. A self-created interval between tablets is not an approved way to bypass that restriction.
Make the existing regimen visible
| Tadalafil situation | Information to bring | Common information gap |
|---|---|---|
| A regular prescription | Strength, schedule, indication and prescriber | Leaving it off a list because it is not taken immediately before sex |
| Occasional use | Strength and the timing of recent doses | Reporting it as "not a regular medicine" and stopping there |
| A combined product | Package, active ingredients and dispensing record | Assuming the product contains only the expected erection medicine |
| A recent change | Old and new instructions and why the change occurred | Describing the current regimen without mentioning recent exposure |
| An uncertain product | Photograph or packaging for professional identification | Guessing the ingredient from appearance or a sales name |
Do not rely on the broad description "an erection pill." The exact ingredient and schedule can change the interaction assessment.
Why the reason for tadalafil use also matters
The clinician needs to understand the treatment target, not just identify a tablet. If erection loss leads you to rush sexual activity, treating the erection concern and treating ejaculation may be different priorities.
Describe whether the early ejaculation began before or after the erection problem. State what tadalafil has changed and what remains difficult. A partial benefit from one medicine does not automatically establish that another should be added.
If different clinicians manage the prescriptions, give each the complete medication information. Separate appointments for separate symptoms can otherwise create separate lists that miss a clinically relevant combination.
A pharmacokinetic finding is not a safety clearance
The Priligy information reports that tadalafil did not change dapoxetine pharmacokinetics in a studied combination. In the same discussion, it retains the restriction concerning PDE5 inhibitors and possible reduced orthostatic tolerance.
These statements are not contradictory. One concerns measured exposure to the drug; the other concerns potential clinical effects, including low blood pressure on standing. An interaction does not have to increase a concentration dramatically to matter.
Therefore, a website quoting only the unchanged blood-level finding has not provided a complete prescribing answer. Nor can a reassuring home measurement replace assessment of the relevant history and regimen.
Why not choose a waiting interval yourself?
An online rule such as "separate the tablets by a few hours" may ignore the exact prescription, drug persistence and patient-specific risks. It can also turn a regular treatment into an uncontrolled pattern of skipped and catch-up doses.
Do not stop tadalafil, postpone it or take extra tablets later simply to create space for Priligy. Ask the prescribing clinician to review the whole plan. The correct decision may involve a different PE treatment rather than a timetable for a restricted combination.
If tadalafil is used only occasionally, disclose recent use anyway. Frequency of use and duration of exposure are different questions, and an intermittent medicine can still matter to the next prescription.
Which symptoms and conditions should be mentioned?
Previous fainting, dizziness on standing and cardiovascular diagnoses are relevant. Include blood-pressure medicines and other treatments that could affect tolerability. Report the symptoms accurately rather than assuming that an episode after a tablet was caused only by dehydration or fatigue.
If both medicines have already been used and you experienced fainting or a severe reaction, seek medical assessment before taking more. The absence of a problem on an earlier occasion is not proof of safe repeated combination use.
Leave with one coherent plan
Confirm which medicine addresses which symptom, which instructions apply now and who will review any change. If an unfamiliar combination product is involved, have its ingredients established before treating it as equivalent to the separate prescriptions.
A practical medication record should contain the active ingredient, strength, schedule and last relevant doses. That record prevents a regular or occasional tadalafil exposure from disappearing between consultations. The aim is coordinated care for the symptoms you have, rather than two prescriptions managed as if neither can affect the other.